📅 Original Article Published: September 25, 2025
💵 Entry (Call Option) Price: $3.50
📆 Exit (GTC Sell to Close): October 23, 2025, at $6.00
📈 Total Gain: +60% Profit — Automatically Triggered
💡 Big Picture
Had you listened to our previous HRMY stock options analysis published on September 25, 2025, and entered the same position at the $3.50 options price, you would have automatically locked in profits when our Good-Til-Canceled (GTC) sell order hit $6.00 on October 23, 2025 — without needing to watch the market day-to-day.
That means a $3,500 investment (10 contracts) would have grown to $6,000, resulting in $2,500 profit.
For 30 contracts ($10,500), that translates into $7,500 profit.
And for 50 contracts ($17,500), that’s an impressive $12,500 gain — all realized automatically.
This win demonstrates the effectiveness of sticking to a predefined strategy, trusting the technical setup, and allowing automation to take emotion out of trading.
Here’s the link to the original stock options analysis article for HRMY: Harmony Biosciences (HRMY) Stock Options Analysis – Contrarian Opportunity After Fragile X Trial Failure
📊 Before & After Chart Comparison
Before Chart (September 25, 2025)
At the time of our initial call, HRMY (Harmony Biosciences Holdings, Inc.) had fallen sharply from the mid-$30s to the $27 zone. The stock was deeply oversold, with an RSI reading of 23.50, signaling extreme bearish sentiment. Meanwhile, the MACD histogram was bottoming out, hinting that downward momentum was exhausting.
This setup fit perfectly into our Twelve-Pillar Hedge Fund Stock Pick Framework, specifically Pillar 7 (Technical Strength) and Pillar 6 (Institutional Accumulation). When both align — meaning a stock is oversold and institutions begin accumulating — the probability of a strong rebound is high.
That’s exactly where HRMY was on September 25: panic-driven overselling setting up a rebound opportunity.
After Chart (October 26, 2025)
By late October, HRMY’s reversal had fully materialized. The stock climbed from $27 to over $30, hitting our +60% GTC profit target exactly as planned. RSI shot up from 23.50 to over 80, confirming an explosive momentum shift. MACD completed a bullish crossover, and the price broke back above the VWAP and 50-day moving average with strong volume.
The outcome was clear:
Our thesis — that oversold levels would reverse as institutional volume stepped in — was confirmed in full.
This trade serves as another textbook example of buying capitulation and selling strength, following a structured and unemotional plan.
🔍 Technical Breakdown
Let’s summarize the technical story of HRMY’s profit run:
- RSI Oversold Recovery: RSI below 25 in late September signaled exhaustion, then a rapid rise above 70 in October confirmed a reversal.
- MACD Cross: The momentum crossover on October 5 signaled a shift from selling pressure to buying momentum.
- Volume Expansion: High-volume up days during the breakout verified institutional accumulation.
- VWAP Recovery: Price reclaiming the VWAP around $29–$30 provided confirmation of trend reversal.
- Momentum Completion: RSI above 80 on October 23 confirmed strong short-term overbought conditions — ideal for profit-taking.
Every major indicator aligned perfectly for our +60% profit capture window.
💰 Profit Perspective
| Contracts | Entry @ $3.50 | Exit @ $6.00 | Profit % | Dollar Gain |
|---|---|---|---|---|
| 10 | $3,500 | $6,000 | +60% | $2,500 |
| 30 | $10,500 | $18,000 | +60% | $7,500 |
| 50 | $17,500 | $30,000 | +60% | $12,500 |
| 100 | $35,000 | $60,000 | +60% | $25,000 |
Had you listened to our previous article and entered a position when we published it, you would have automatically profited between $2,500 and $25,000, depending on your position size — all within a single month and entirely hands-free.
🧩 Institutional & Options Flow Recap
During October, institutional options flow in HRMY remained bullish:
- Call Option Accumulation: Notable call-buying activity across mid-2026 expirations indicated ongoing confidence.
- Put/Call Ratio: Held steady around 0.68, a bullish skew suggesting traders favored upside.
- Open Interest: Grew by over 25% on call contracts during the profit run, showing active participation from larger players.
These signals reinforce that this move wasn’t a retail-driven bounce — it was powered by smart money accumulation at the lows.
🗞️ Catalyst Review
- Earnings Strength: HRMY’s Q3 report confirmed solid revenue growth from its neurology and sleep-disorder portfolios.
- Clinical Pipeline: Ongoing positive developments from its narcolepsy treatment trials added long-term credibility.
- Analyst Coverage: JPMorgan, Barclays, and other firms maintained Buy or Overweight ratings, with price targets ranging $40–$46.
These catalysts added strong fundamental backing to an already bullish technical reversal — a rare and profitable combination.
🚀 Key Takeaways
- ✅ Discipline Wins: The GTC sell order ensured we exited at peak conditions without emotional interference.
- ✅ Perfect Timing: Entry aligned with RSI bottoming, and exit coincided with RSI topping — maximizing the move.
- ✅ Institutional Footprint: Smart money accumulation confirmed the validity of our thesis.
- ✅ Simple, Repeatable Process: Enter technical exhaustion, automate the exit, and let data drive the outcome.
HRMY’s +60% trade perfectly reflects the power of data-driven, automated discipline that underpins every VIXTradingHub strategy.
⚠️ Legal & Risk Disclaimer
This report is for educational and informational purposes only and should not be construed as financial advice or a solicitation to buy or sell any security or option contract.
Trading options involves significant risk of loss and may not be suitable for all investors.
Past performance does not guarantee future results.
All trade examples are hypothetical illustrations based on market data at the time of writing.
Always conduct independent research and consult a licensed financial advisor before trading.
VIXTradingHub.com, its affiliates, and authors assume no liability for financial losses resulting from reliance on this analysis.
We currently hold no active position in HRMY.
Allocate no more than 2% of your total capital to any single options trade to manage portfolio risk.
🏁 Final Trade Summary
- ✅ Trade: HRMY 500 DTE Call Option
- 🎯 Entry: $3.50
- 🏆 Exit (GTC): $6.00
- 💵 Profit: +60% in less than 1 month
- 📉 Status: Trade completed, no re-entry planned
